{"id":"https://openalex.org/W7225628016","doi":"https://doi.org/10.1021/acs.molpharmaceut.6c00463","title":"ABCB1, ABCG2, and CES1 are Key Determinants of the Pharmacokinetics of KRASG12C Inhibitor Divarasib","display_name":"ABCB1, ABCG2, and CES1 are Key Determinants of the Pharmacokinetics of KRASG12C Inhibitor Divarasib","publication_year":2026,"publication_date":"2026-11-09","ids":{"openalex":"https://openalex.org/W7225628016","doi":"https://doi.org/10.1021/acs.molpharmaceut.6c00463"},"language":"en","primary_location":{"id":"doi:10.1021/acs.molpharmaceut.6c00463","doi":"https://doi.org/10.1021/acs.molpharmaceut.6c00463","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.molpharmaceut.6c00463","pdf_url":null,"source":{"id":"https://openalex.org/S204562082","display_name":"Molecular Pharmaceutics","issn_l":"1543-8384","issn":["1543-8384","1543-8392"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Pharmaceutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015979847","display_name":"Jamie Rijmers","orcid":"https://orcid.org/0009-0009-2131-7422","observed_orcids":["https://orcid.org/0009-0009-2131-7422"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Jamie Rijmers","raw_affiliation_strings":["The Netherlands Cancer Institute , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Netherlands Cancer Institute , , ,","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078854275","display_name":"Vi\u00ebt Bui","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Vie\u0308t Bui","raw_affiliation_strings":["The Netherlands Cancer Institute , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Netherlands Cancer Institute , , ,","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161311962","display_name":"Danie\u0308lle C. Band","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Danie\u0308lle C. Band","raw_affiliation_strings":["The Netherlands Cancer Institute , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Netherlands Cancer Institute , , ,","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161355669","display_name":"Wenlong Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I241749","display_name":"University of Cambridge","ror":"https://ror.org/013meh722","country_code":"GB","type":"education","lineage":["https://openalex.org/I241749"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Wenlong Li","raw_affiliation_strings":["University of Cambridge , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Cambridge , , ,","institution_ids":["https://openalex.org/I241749"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077577302","display_name":"Liesbeth Hoekman","orcid":"https://orcid.org/0000-0002-3552-6390","observed_orcids":["https://orcid.org/0000-0002-3552-6390"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Liesbeth Hoekman","raw_affiliation_strings":["The Netherlands Cancer Institute , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Netherlands Cancer Institute , , ,","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066696136","display_name":"Onno B. Bleijerveld","orcid":"https://orcid.org/0000-0002-9395-2347","observed_orcids":["https://orcid.org/0000-0002-9395-2347"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Onno B. Bleijerveld","raw_affiliation_strings":["The Netherlands Cancer Institute , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Netherlands Cancer Institute , , ,","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5097606559","display_name":"Davinia Arguedas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Davinia Arguedas","raw_affiliation_strings":["The Netherlands Cancer Institute , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Netherlands Cancer Institute , , ,","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034151807","display_name":"Olaf van Tellingen","orcid":"https://orcid.org/0000-0002-1037-6269","observed_orcids":["https://orcid.org/0000-0002-1037-6269"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Olaf van Tellingen","raw_affiliation_strings":["The Netherlands Cancer Institute , , ,"],"raw_orcid":"https://orcid.org/0000-0002-1037-6269","affiliations":[{"raw_affiliation_string":"The Netherlands Cancer Institute , , ,","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020507978","display_name":"Maria Cristina Lebre","orcid":"https://orcid.org/0000-0002-9234-4227","observed_orcids":["https://orcid.org/0000-0002-9234-4227"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Maria C. Lebre","raw_affiliation_strings":["The Netherlands Cancer Institute , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Netherlands Cancer Institute , , ,","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041124699","display_name":"J.H. Beijnen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I193662353","display_name":"Utrecht University","ror":"https://ror.org/04pp8hn57","country_code":"NL","type":"education","lineage":["https://openalex.org/I193662353"]},{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Jos H. Beijnen","raw_affiliation_strings":["The Netherlands Cancer Institute , , ,","Utrecht University , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Netherlands Cancer Institute , , ,","institution_ids":["https://openalex.org/I2898336195"]},{"raw_affiliation_string":"Utrecht University , , ,","institution_ids":["https://openalex.org/I193662353"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045217576","display_name":"Alfred H. Schinkel","orcid":"https://orcid.org/0000-0002-4215-8602","observed_orcids":["https://orcid.org/0000-0002-4215-8602"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Alfred H. Schinkel","raw_affiliation_strings":["The Netherlands Cancer Institute , , ,"],"raw_orcid":"https://orcid.org/0000-0002-4215-8602","affiliations":[{"raw_affiliation_string":"The Netherlands Cancer Institute , , ,","institution_ids":["https://openalex.org/I2898336195"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5045217576"],"corresponding_institution_ids":["https://openalex.org/I2898336195"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9711999893188477,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9711999893188477,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.027400000020861626,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10147","display_name":"Antibiotic Resistance in Bacteria","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2726","display_name":"Microbiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8808000087738037},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7067000269889832},{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.6320000290870667},{"id":"https://openalex.org/C149011108","wikidata":"https://www.wikidata.org/wiki/Q652985","display_name":"Transporter","level":3,"score":0.6128000020980835},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5730000138282776},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5440000295639038},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4447000026702881},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.4375},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.4226999878883362},{"id":"https://openalex.org/C200082930","wikidata":"https://www.wikidata.org/wiki/Q22327148","display_name":"Efflux","level":2,"score":0.414900004863739},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.382099986076355},{"id":"https://openalex.org/C110121322","wikidata":"https://www.wikidata.org/wiki/Q865811","display_name":"Distribution (mathematics)","level":2,"score":0.3799999952316284},{"id":"https://openalex.org/C512196","wikidata":"https://www.wikidata.org/wiki/Q4650095","display_name":"Abcg2","level":5,"score":0.37369999289512634},{"id":"https://openalex.org/C44312359","wikidata":"https://www.wikidata.org/wiki/Q286958","display_name":"ATP-binding cassette transporter","level":4,"score":0.3479999899864197},{"id":"https://openalex.org/C11824378","wikidata":"https://www.wikidata.org/wiki/Q5014970","display_name":"CYP3A","level":4,"score":0.3463999927043915},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.32179999351501465},{"id":"https://openalex.org/C3020079912","wikidata":"https://www.wikidata.org/wiki/Q3918988","display_name":"Plasma concentration","level":2,"score":0.30889999866485596},{"id":"https://openalex.org/C36201501","wikidata":"https://www.wikidata.org/wiki/Q17907816","display_name":"Multidrug resistance-associated protein 2","level":5,"score":0.27320000529289246},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.2662000060081482},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.26269999146461487},{"id":"https://openalex.org/C2776980637","wikidata":"https://www.wikidata.org/wiki/Q427492","display_name":"Enzyme inhibitor","level":3,"score":0.2565999925136566}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1021/acs.molpharmaceut.6c00463","doi":"https://doi.org/10.1021/acs.molpharmaceut.6c00463","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.molpharmaceut.6c00463","pdf_url":null,"source":{"id":"https://openalex.org/S204562082","display_name":"Molecular Pharmaceutics","issn_l":"1543-8384","issn":["1543-8384","1543-8392"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Pharmaceutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W1999363531","https://openalex.org/W2010427019","https://openalex.org/W2105991296","https://openalex.org/W2123002505","https://openalex.org/W2325140777","https://openalex.org/W2404239255","https://openalex.org/W2501247313","https://openalex.org/W2810653208","https://openalex.org/W2982466751","https://openalex.org/W2995199382","https://openalex.org/W3019065741","https://openalex.org/W3131881635","https://openalex.org/W4213254888","https://openalex.org/W4292315419","https://openalex.org/W4307266448","https://openalex.org/W4323294592","https://openalex.org/W4378084486","https://openalex.org/W4378799462","https://openalex.org/W4379600667","https://openalex.org/W4382399926","https://openalex.org/W4385824102","https://openalex.org/W4386116142","https://openalex.org/W4389338940","https://openalex.org/W4396662372","https://openalex.org/W4396841208","https://openalex.org/W4396870520","https://openalex.org/W4401335341","https://openalex.org/W4411116920","https://openalex.org/W4414621184","https://openalex.org/W7133241897","https://openalex.org/W7169668131"],"related_works":[],"abstract_inverted_index":{"Abstract":[0],"Divarasib":[1,97],"is":[2],"a":[3,114],"selective":[4],"KRASG12C":[5],"inhibitor":[6,148],"currently":[7],"in":[8,107,117,138,150,161,210],"phase":[9],"3":[10],"trials":[11],"for":[12],"treatment":[13],"of":[14,53,144,204,217,226,238],"NSCLC.":[15],"Drug":[16],"transporters":[17,33],"and":[18,35,41,45,50,60,66,78,94,105,110,120,140,177,243,245],"metabolic":[19],"enzymes":[20,43],"can":[21],"markedly":[22],"influence":[23],"oral":[24,75,184],"drug":[25],"disposition.":[26],"We":[27],"therefore":[28],"examined":[29],"whether":[30],"the":[31,37,42,48,145,158],"efflux":[32],"ABCB1":[34],"ABCG2,":[36],"influx":[38],"transporter":[39],"OATP1,":[40],"CYP3A":[44],"CES1":[46],"affect":[47],"plasma":[49,89,118,155,191,196,201],"tissue":[51,91,208],"distribution":[52],"divarasib.":[54],"Using":[55],"genetically":[56],"modified":[57],"cell":[58],"lines":[59],"mouse":[61],"models,":[62],"we":[63],"assessed":[64],"transporter-":[65],"enzyme-mediated":[67],"effects":[68],"on":[69],"divarasib":[70,87,154,175,190,199,218,228,239],"pharmacokinetics.":[71],"Transepithelial":[72],"transport":[73],"assays,":[74],"pharmacokinetic":[76,233],"studies,":[77],"ex":[79],"vivo":[80],"esterase":[81],"assays":[82],"were":[83,135],"performed":[84],"to":[85,122,128,157,195],"evaluate":[86],"transport,":[88],"exposure,":[90,192],"distribution,":[92],"metabolism,":[93],"protein":[95],"binding.":[96],"was":[98],"efficiently":[99],"transported":[100],"by":[101,219],"hABCB1,":[102],"mAbcb1a,":[103],"hABCG2":[104],"mAbcg2":[106],"vitro.":[108],"Abcb1a/b\u2212/\u2212":[109,139],"Abcb1a/b;Abcg2\u2212/\u2212":[111,141,162],"mice":[112,152,212],"displayed":[113],">4-fold":[115],"increase":[116],"exposure":[119,156],"7.1-":[121],"16-fold":[123],"higher":[124],"brain-to-plasma":[125],"ratios":[126,134],"compared":[127],"wild-type":[129,151],"mice.":[130,142],"Small":[131],"intestinal":[132],"content-to-plasma":[133],"significantly":[136],"reduced":[137],"Coadministration":[143],"dual":[146],"ABCB1/ABCG2":[147],"elacridar":[149],"increased":[153],"level":[159],"seen":[160],"mice,":[163],"but":[164],"only":[165],"modestly":[166],"enhanced":[167],"brain":[168],"penetration.":[169],"Oatp1a/b":[170],"deficiency":[171],"did":[172],"not":[173],"alter":[174],"pharmacokinetics,":[176],"neither":[178],"mCyp3a":[179],"nor":[180],"hCYP3A4":[181],"affected":[182],"its":[183],"availability.":[185],"Ces1":[186,221],"ablation":[187],"strongly":[188],"decreased":[189,215],"suggesting":[193],"binding":[194],"Ces1c.":[197],"Accordingly,":[198],"inhibited":[200],"Ces1c-mediated":[202],"hydrolysis":[203,216],"4-nitrophenyl":[205],"acetate.":[206],"Increased":[207],"concentrations":[209],"Ces1\u2212/\u2212":[211],"further":[213],"suggested":[214],"(non-Ces1c)":[220],"enzymes,":[222],"or":[223],"compensatory":[224],"downregulation":[225],"other":[227],"clearance":[229],"process(es).":[230],"The":[231],"obtained":[232],"insights":[234],"may":[235],"support":[236],"optimization":[237],"clinical":[240],"application,":[241],"efficacy":[242],"safety,":[244],"highlight":[246],"potential":[247],"drug\u2212drug":[248],"interaction":[249],"risks.":[250]},"counts_by_year":[],"updated_date":"2026-11-10T13:44:29.811591","created_date":"2026-11-10T00:00:00"}